ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

ARTES Biotech­nol­o­gy and Bur­net Insti­tute announce they have joined forces to devel­op a nov­el, effec­tive vac­cine to pre­vent trans­mis­sion of hepati­tis C virus (HCV).

An HCV vac­cine is urgent­ly need­ed to pre­vent re-infec­tion in peo­ple treat­ed through antivi­ral ther­a­pies and reverse the high glob­al mor­tal­i­ty rates from infec­tion-relat­ed liv­er cir­rho­sis or liv­er can­cer, esti­mat­ed by the World Health Orga­ni­za­tion (WHO) to be more than 500,000 peo­ple each year. More than 130 mil­lion peo­ple glob­al­ly are car­ri­ers of HCV, a blood-borne virus.

The inno­v­a­tive hepati­tis C vac­cine project will com­bine Bur­nets’ pro­pri­etary HepSeeVaxDelta3™ tech­nol­o­gy, devel­oped by Asso­ciate Pro­fes­sor Hei­di Drum­mer and col­leagues, with ARTES’ pro­pri­etary METAVAX® tech­nol­o­gy for the devel­op­ment of chimeric virus-like par­ti­cle (VLP) based vac­cines. The project aims to devel­op a VLP based vac­cine that effi­cient­ly presents HCV anti­gens to pre­vent hepati­tis C infec­tion. The VLPs will present the nov­el, mod­i­fied enve­lope pro­tein (E2) on its sur­face, there­by tar­get­ing the vac­cine to den­drit­ic cells to prime and pre­pare the immune sys­tem to fight against hepati­tis C infec­tion.

Deputy Head of Burnet’s Cen­tre for Bio­med­ical Research and HCV vac­cine team leader, Asso­ciate Pro­fes­sor Drum­mer said HepSeeVaxDelta3™ tech­nol­o­gy over­comes a crit­i­cal lim­i­ta­tion to HCV vac­cine devel­op­ment. “The virus that caus­es HCV has evolved to avoid the immune sys­tem so that in nat­ur­al infec­tion, key immune respons­es are delayed or dis­tract­ed by irrel­e­vant tar­gets on the virus. The same is true for con­ven­tion­al vac­cine plat­forms test­ed pre­vi­ous­ly. The HepSeeVaxDelta3™ com­po­nent of the vac­cine redi­rects the immune response to make anti­bod­ies on the most impor­tant tar­gets that pre­vent infec­tion against the sev­en cir­cu­lat­ing HCV geno­types.”

Man­ag­ing Direc­tor of ARTES, Dr Michael Pio­ntek said his com­pa­ny was excit­ed to join forces with Bur­net Insti­tute to devel­op a much-need­ed vac­cine against hepati­tis C, which is endem­ic in many coun­tries where treat­ment costs are high and HCV pos­es a sig­nif­i­cant bur­den on health­care sys­tems. “Access to diag­no­sis and treat­ment is lim­it­ed, espe­cial­ly in endem­ic coun­tries in Africa and Asia, so there is a strong demand for a safe and low-cost vac­cine to pre­vent hepati­tis C infec­tion. This is in-line with the aim of the WHO to real­ize their hepati­tis C elim­i­na­tion tar­gets. After out-licens­ing process­es for hepati­tis B vac­cine pro­duc­tion world­wide, ARTES is proud to take the next step togeth­er with Bur­net Insti­tute in fight­ing anoth­er life-threat­en­ing hepati­tis infec­tion.”


The vac­cine devel­op­ment plat­form

ARTES’ vac­cine devel­op­ment plat­form METAVAX® in com­bi­na­tion with the expres­sion host Hansenu­la poly­mor­pha (rec­om­mend­ed by the WHO for hepati­tis B vac­cine pro­duc­tion) is the pre­ferred tool for the devel­op­ment of afford­able vac­cines. ARTES’ devel­op­ment plat­form is a unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.

Bur­net Institute’s HepSeeVaxDelta3™ tech­nol­o­gy is devel­oped by re-engi­neer­ing the major HCV viral sur­face pro­tein E2 to pro­duce the nov­el HepSeeVaxDelta3™ vac­cine. HepSeeVaxDelta3™ can gen­er­ate high lev­els of anti­bod­ies that can block repli­ca­tion of all sev­en geno­types of HCV in lab­o­ra­to­ry tests. This major sci­en­tif­ic advance offers the prospect of a sim­ple, uni­ver­sal vac­cine to pre­vent HCV infec­tion world­wide.

ARTES and Biosphere announce collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for recom­bi­nant pro­tein pro­duc­tion and tech­nol­o­gy provider for high-qual­i­ty biotech­no­log­i­cal process­es, join forces with the well-estab­lished con­tract man­u­fac­tur­ing com­pa­ny Bios­phere. Aim of this pre­ferred coop­er­a­tion is to offer a full range of ser­vices, start­ing from cell line gen­er­a­tion up to indus­tri­al scale man­u­fac­tur­ing in one pack­age. The com­bi­na­tion of the dif­fer­ent exper­tise, know-how and infra­struc­ture of the two com­pa­nies will flow direct­ly into one com­mon offer. This offer address­es cus­tomers who are look­ing for devel­op­ment of enzymes and pro­teins cur­rent­ly applied in the phar­ma­ceu­ti­cal, food and fine chem­i­cal sec­tor.

ARTES offers manufacturing of preclinical samples up to multi-gram scale

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for the phar­ma­ceu­ti­cal indus­try recent­ly expand­ed its ser­vice port­fo­lio and sup­plied sam­ples for pre­clin­i­cal test­ing to a first client.

With the new equipped pilot plant for pro­duc­tion of nonGMP mate­r­i­al, we are now in the posi­tion to pro­vide our clients with high qual­i­ty pre­clin­i­cal test mate­r­i­al in gram amounts”, Michael Weniger Head of Process Devel­op­ment at ARTES stat­ed. “Thanks to our exist­ing expe­ri­ence, instal­la­tion of the plant at ARTES, imple­men­ta­tion of a new process and sup­ply of a batch have been man­aged with­in three months. The chal­lenge in this kind of fast track projects is very often to meet a high qual­i­ty stan­dard”, Weniger point­ed out.


For more detailed infor­ma­tion and for an offer please con­tact us.

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion, process and vac­cine devel­op­ment from micro­bial expres­sion sys­tems announces a col­lab­o­ra­tion with the glob­al phar­ma­ceu­ti­cal com­pa­ny Boehringer Ingel­heim Ani­mal Health.

ARTES’ expres­sion sys­tem Hansenu­la poly­mor­pha is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and rec­om­mend­ed by the World Health Orga­ni­za­tion (WHO) for these pur­pos­es. In com­bi­na­tion with ARTESMETAVAX® plat­form, this offers a new, unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines required in the vet­eri­nary field.

This col­lab­o­ra­tion is anoth­er mile­stone in expand­ing our vac­cine devel­op­ment exper­tise”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “We are more than con­fi­dent that our tech­nol­o­gy plat­form is per­fect­ly suit­ed for the devel­op­ment of safe and cost effi­cient vac­cines that are high­ly rel­e­vant for the vet­eri­nary mar­ket.”

Part­ner­ing is a cen­tral part of our strat­e­gy. We are excit­ed about this col­lab­o­ra­tion and the oppor­tu­ni­ty to devel­op more inno­v­a­tive vac­cines for the ani­mal health mar­ket,” says Rolf-Dieter Gün­ther, Head of Glob­al Busi­ness Devel­op­ment and Licens­ing Ani­mal Health for Boehringer Ingel­heim.

ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

Under the title:” devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions”, in short “Pluri­vax”, the EU coop­er­a­tion is part of the recent 8th Euro­Trans­Bio call and will be fund­ed for a three year peri­od sup­port­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).

The intent of “Pluri­vax” is to devel­op a sta­ble pro­duc­tion plat­form and an adapt­ed high-qual­i­ty process to have an effec­tive and usable inte­grat­ed best prac­tice suit­able for sev­er­al vet­eri­nary vaccines.The plat­form result­ing from this project will be the first of its kind in vet­eri­nary appli­ca­tion and thus opens access to a huge mar­ket. A robust, inex­pen­sive vac­cine will reduce the need for antibi­ot­ic treat­ment of food ani­mals, there­by direct­ly reduc­ing pro­duc­tion costs and improv­ing qual­i­ty of life for the food ani­mal itself and for the con­sumer.

ARTES VLP plat­form METAVAX® has already been applied to the devel­op­ment of adju­vant-free vac­cines against dif­fer­ent dis­eases like avian and swine flu, malar­ia and HIV. Our yeast expres­sion host Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Togeth­er, our plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines”, Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES.

Annie Van Broekhoven, CEO Q-Bio­log­i­cals com­ments: “We will employ our know-how and exper­tise in the field of bio­process devel­op­ment, man­u­fac­tur­ing and for­mu­la­tion of recom­bi­nant anti­gens to devel­op a robust pro­duc­tion process for VLP based vac­cines. We are con­fi­dent that we will suc­ceed in short­en­ing the process devel­op­ment times con­sid­er­ably, and in doing so dri­ve down devel­op­ment costs and sup­port rapid mar­ket intro­duc­tion.”

We will con­tribute our tai­lor made but com­pet­i­tive­ly priced plat­form purifi­ca­tion process to this cost sen­si­tive pro­duc­tion process­es. Our pro­pri­etary chro­matog­ra­phy phase tech­nol­o­gy, already being used for purifi­ca­tion of com­mer­cial bio­phar­ma­ceu­ti­cals and small mol­e­cule APIs, allows spe­cif­ic bind­ing of tar­get mol­e­cules and can be trans­ferred to almost every chro­mato­graph­ic car­ri­er sub­strate”, Peter Kallien, CFO of instrAc­tion.

Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project

ARTES Biotech­nol­o­gy and Bur­net Insti­tute have joined forces to devel­op a new type of malar­ia vac­cine in a project fund­ed by the PATH Malar­ia Vac­cine Ini­tia­tive (MVI).

The project will use excit­ing nov­el tech­nol­o­gy devel­oped at the Bur­net Insti­tute. ARTES holds the inter­na­tion­al patent rights and adapt­ed the plat­form to vac­cine pro­duc­tion (known as the Metavax® plat­form).

Puri­fied vac­cine anti­gens (Pfs25 and Pfs230) will be pro­duced as virus-like par­ti­cles (VLPs, a type of nano-par­ti­cle) for test­ing in lab­o­ra­to­ry stud­ies. The VLPs will be tak­en up by immune cells to prime and pre­pare the immune sys­tem to fight malar­ia.

The project will focus on strate­gies to pro­duce vac­cines that can block the trans­mis­sion of malar­ia infec­tion from mos­qui­toes to peo­ple, as part of a pro­gram fund­ed by MVI.

Strategic cooperation between ARTES & Sun Pharma

ARTES Biotech­nol­o­gy has entered into a strate­gic col­lab­o­ra­tion with a sub­sidiary of Sun Phar­ma­ceu­ti­cal Indus­tries Ltd, an inter­na­tion­al spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny with a diver­si­fied prod­uct port­fo­lio head­quar­tered in Mumbai/India.

This step broad­ens ARTES’ inter­na­tion­al client base and demon­strates its abil­i­ty to attract blue chip phar­ma­ceu­ti­cal com­pa­nies. Under the col­lab­o­ra­tion agree­ment, ARTES will be respon­si­ble to deliv­er top-class cell lines and pro­duc­tion process­es for sev­er­al phar­ma­ceu­ti­cal tar­gets.

As part of the strate­gic col­lab­o­ra­tion, Sun Pharma’s sub­sidiary will also become a minor­i­ty share­hold­er in ARTES.

Vaccine Emerging Markets

Meet us at the 2nd Annu­al Pha­cil­i­tate Part­ner­ing for Vac­cine Emerg­ing Mar­kets event in Ams­ter­dam, May 28th -29th or con­tact us pre­vi­ous­ly for a per­son­al meet­ing!

We look for­ward to meet­ing you!

EU Research Project “Nano3Bio” has Started – “Huge Potential” through Biotechnology

ARTES Biotech­nol­o­gy GmbH is part of the inter­na­tion­al con­sor­tium

While the oil is slow­ly but sure­ly run­ning out, renew­able resources are becom­ing increas­ing­ly impor­tant. In future, the bio­log­i­cal pro­duc­tion of raw mate­ri­als has to play an even greater role to meet the needs in an envi­ron­men­tal­ly friend­ly man­ner. An inter­na­tion­al con­sor­tium of researchers and com­pa­nies now ris­es to this chal­lenge. Its goal is the biotech­no­log­i­cal pro­duc­tion of so-called chi­tosans, which are used as raw mate­ri­als for med­i­cine, agri­cul­ture, water treat­ment, cos­met­ics, paper and tex­tile indus­tries as well as many oth­er fields of appli­ca­tion. To tap this poten­tial, the Euro­pean Com­mis­sion sup­ports the research project “Nano3Bio” with a total of almost 9 mil­lion Euros up to 2017. In addi­tion to the experts from ARTES, uni­ver­si­ties and research insti­tutes as well as com­pa­nies from Bel­gium, Den­mark, France, Ger­many, India, The Nether­lands, Spain and Swe­den are involved. They recent­ly met to kick off the project in Mün­ster, Ger­many.

The Nano3Bio project is mak­ing a sci­en­tif­ic dream come true, because this strong con­sor­tium will be able to achieve a break­through from basic research to the biotech­no­log­i­cal pro­duc­tion of chi­tosans”, says Pro­fes­sor Dr. Bruno Moer­schbach­er, biol­o­gist at the Uni­ver­si­ty of Mün­ster and coor­di­na­tor of the project.

ARTES Biotechnology joins TA101 GOCLIN

A lead­ing con­sor­tium of indus­tri­al part­ners has been award­ed a grant by the Sev­enth Frame­work Pro­gram of the Euro­pean Union for an inno­v­a­tive research and devel­op­ment project “TA101 GOCLIN: Clin­i­cal devel­op­ment of TA-101 for the treat­ment of rheuma­toid arthri­tis“ (#606352). The aim of this Project is to take TA101, a small domain anti­body devel­oped by TechnoPhage, into the clin­i­cal stage of devel­op­ment for rheuma­toid arthri­tis (RA) and devel­op a nov­el mode of admin­is­tra­tion for the mar­ket of bio­log­ic ther­a­peu­tics. The project is fore­cast­ed for com­ple­tion in 2015, with a total dura­tion of 26 months. The total bud­get is EUR 1,72 mil­lion cor­re­spond­ing to a total Euro­pean fund­ing of EUR 1,36 mil­lion.

TA101 GOCLIN has mobi­lized the crit­i­cal mass of sev­en indus­tri­al part­ners from 5 Euro­pean coun­tries. These part­ners are from Bel­gium, France, Ger­many, The Nether­lands and Por­tu­gal.

Amspar B.V will design and devel­op an inte­grat­ed micronee­dle patch com­bi­na­tion loaded with TA_101. In this regard, Amspar will close­ly work togeth­er with Lab­o­ra­toires Plas­to San­té (expert in phar­ma­ceu­ti­cal patch devel­op­ment) and Micro­Cre­ate BV (micronee­dle array man­u­fac­tur­ing).
Q-Bio­log­i­cals NV togeth­er with ARTES Biotech­nol­o­gy GmbH will devel­op a suit­able micro­bial expres­sion host and man­u­fac­tur­ing process. cGMP mate­r­i­al for clin­i­cal tri­als will be pro­duced by Q-Bio­log­i­cals.
Clin­i­cal tri­als will be con­duct­ed by SGS Life Sci­ence Ser­vices.